ANRIL has been proposed to regulate vascular cell inflammation, viability, proliferation, and senescence, thereby providing novelty for the future atherosclerosis therapies [71, 73, 75–77]. This evidence concerns the gene CDKN2B-AS1 and atherosclerosis.